These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 85038)

  • 1. Propranolol in uraemic osteodystrophy.
    Eastwood JB
    Lancet; 1979 Feb; 1(8112):386-7. PubMed ID: 85038
    [No Abstract]   [Full Text] [Related]  

  • 2. Propranolol in uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Ponticelli C
    Lancet; 1978 Oct; 2(8096):940. PubMed ID: 81949
    [No Abstract]   [Full Text] [Related]  

  • 3. Effect of chronic propranolol treatment on bone changes of secondary hyperparathyroidism in dialysis patients.
    Pizzarelli F; Zoccali C; Ciccarelli C; Maggiore Q; Bonucci E; Ballanti P
    Nephron; 1982; 32(1):93-4. PubMed ID: 7177287
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propranolol and uraemic osteodystrophy.
    Brancaccio D; Galmozzi C; Casati S; Rurale D; Belloli S; Aroldi A; Graziani G; Ponticelli C
    Proc Eur Dial Transplant Assoc; 1979; 16():668-71. PubMed ID: 549007
    [No Abstract]   [Full Text] [Related]  

  • 5. Calcimimetics: a new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease.
    Lindberg JS
    Kidney Int Suppl; 2005 Jun; (95):S33-6. PubMed ID: 15882311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of secondary hyperparathyroidism by propranolol in renal failure patients.
    Besarab A; Caro JF; Ihle BU; Burke JF; Glennon JA; Fischer JA
    Nephron; 1981; 27(3):127-33. PubMed ID: 7219643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A possible role for propranolol in the treatment of renal osteodystrophy.
    Caro JF; Besarab A; Burke JF; Glennon JA
    Lancet; 1978 Aug; 2(8087):451-4. PubMed ID: 79809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Secondary hyperparathyroidism and tertiary hyperparathyroidism chronic renal failure, uremia].
    Morio K; Koide K
    Nihon Rinsho; 1995 Apr; 53(4):958-64. PubMed ID: 7752492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockers of beta and H2 receptors and secondary hyperparathyroidism in uraemia.
    Makdassi R; Decourcelle PH; Moriniere P; Coevoet B; de Fremont JF; Kassouf J; Roussel A; Gheerbrand JD; Andrejak M; Fournier A
    Proc Eur Dial Transplant Assoc; 1981; 18():642-7. PubMed ID: 7329992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Azotaemic osteodystrophy-present position.
    Malhotra KK
    J Assoc Physicians India; 1978 Sep; 26(9):827-35. PubMed ID: 370080
    [No Abstract]   [Full Text] [Related]  

  • 11. [Renal osteodystrophy and secondary hyperparathyroidism].
    Zhu J
    Zhonghua Nei Ke Za Zhi; 1995 Mar; 34(3):150. PubMed ID: 7648931
    [No Abstract]   [Full Text] [Related]  

  • 12. Propranolol therapy for secondary hyperparathyroidism in uraemia.
    Fournier A; Coevoet B; de Fremont JF; Gueris J; Caillens G; Desplan C; Calmette C; Moukhtar MS
    Lancet; 1978 Jul; 2(8079):50-1. PubMed ID: 78252
    [No Abstract]   [Full Text] [Related]  

  • 13. Parathyroid function in uremic children with and without osteodystrophy.
    Roof BS; Piel CF; Rames L; Potter D; Gordan GS
    Pediatrics; 1974 Mar; 53(3):404-9. PubMed ID: 4815261
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of propranolol and atenolol in the control of hyperparathyroidism in uremia.
    Makdassi R; Andrejak M; Morinière P; Sebert JL; Decourt S; Guéris J; Coevoet B; Fournier A
    Adv Exp Med Biol; 1982; 151():667-76. PubMed ID: 7180669
    [No Abstract]   [Full Text] [Related]  

  • 15. Vitamin D therapy in uremic osteodystrophy: theoretical and practical considerations.
    Popovtzer MM
    Int J Artif Organs; 1980 Jan; 3(1):1-4. PubMed ID: 7353907
    [No Abstract]   [Full Text] [Related]  

  • 16. The clinical consequences of secondary hyperparathyroidism: focus on clinical outcomes.
    Hörl WH
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V2-8. PubMed ID: 15284353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Sevelamer hydrochloride and K/DOQI guidelines].
    Yumita S
    Clin Calcium; 2005 Sep; 15 Suppl 1():180-4. PubMed ID: 16279022
    [No Abstract]   [Full Text] [Related]  

  • 18. Renal osteodystrophy in dialyzed children.
    Salusky IB; Goodman WG
    Miner Electrolyte Metab; 1991; 17(4):273-80. PubMed ID: 1813790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term treatment of secondary hyperparathyroidism in the chronic hemodialysis patient with 1,25-(OH)2D3].
    Giachino G; Giacchino F; Jeantet A; Del Piano A; Garetto A; Pellerey M; Piccoli G
    Minerva Med; 1985 Mar; 76(9-10):407-14. PubMed ID: 2984605
    [No Abstract]   [Full Text] [Related]  

  • 20. [Monstrous tumourous changes of the facial bones in secondary hyperparathyroidism (author's transl)].
    Pfeifle J; Koch H; Grabensee B; Knieriem HI
    Dtsch Med Wochenschr; 1974 Mar; 99(9):389-91. PubMed ID: 4828634
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.